In This Article:
As the global markets react positively to the recent U.S.-China tariff suspension, Asian equities have shown resilience with Chinese stocks rallying on hopes of reduced trade tensions. In such a climate, identifying growth companies with substantial insider ownership can be particularly appealing, as high insider stakes often signal confidence in a company's future prospects and alignment with shareholder interests.
Top 10 Growth Companies With High Insider Ownership In Asia
| Name | Insider Ownership | Earnings Growth |
| Sineng ElectricLtd (SZSE:300827) | 36% | 26.8% |
| Nanya New Material TechnologyLtd (SHSE:688519) | 11% | 63.1% |
| Schooinc (TSE:264A) | 26.6% | 68.9% |
| Global Tax Free (KOSDAQ:A204620) | 20.8% | 35.1% |
| Fulin Precision (SZSE:300432) | 13.6% | 44.2% |
| Oscotec (KOSDAQ:A039200) | 21.1% | 85.9% |
| Zhejiang Leapmotor Technology (SEHK:9863) | 15.6% | 60.7% |
| giftee (TSE:4449) | 34.5% | 63.7% |
| Suzhou Sunmun Technology (SZSE:300522) | 35.4% | 77.7% |
| Techwing (KOSDAQ:A089030) | 18.8% | 65% |
We're going to check out a few of the best picks from our screener tool.
MIXUE Group
Simply Wall St Growth Rating: ★★★★☆☆
Overview: MIXUE Group operates in the production and sale of fruit drinks, tea drinks, ice cream, and coffee products both in Mainland China and internationally, with a market cap of HK$195.69 billion.
Operations: The company's revenue is primarily derived from franchise and related services (CN¥620.05 million), sales of goods (CN¥23.45 billion), and sales of equipment (CN¥756.37 million).
Insider Ownership: 28.8%
MIXUE Group, recently completing an HKD 3.45 billion IPO, demonstrates strong growth potential with earnings forecasted to grow at 16.1% annually, outpacing the Hong Kong market's average. Despite high share price volatility and moderate revenue growth projections of 13.4%, the company's high insider ownership aligns interests with shareholders. Recent changes in share capital structure following a full exercise of the over-allotment option reflect strategic adjustments post-IPO to support its expansion ambitions in Asia.
-
Click to explore a detailed breakdown of our findings in MIXUE Group's earnings growth report.
-
Upon reviewing our latest valuation report, MIXUE Group's share price might be too optimistic.
Akeso
Simply Wall St Growth Rating: ★★★★★★
Overview: Akeso, Inc., a biopharmaceutical company, focuses on the research, development, manufacturing, and commercialization of antibody drugs with a market cap of approximately HK$74.99 billion.
Operations: The company's revenue is primarily derived from the research, development, production, and sale of biopharmaceutical products, totaling CN¥2.12 billion.